Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 25, 2025

PaTu 8988t

RRID:CVCL_1847
Type: Cell Line

Proper Citation

(RRID:CVCL_1847)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1847

Proper Citation: (RRID:CVCL_1847)

Sex: Female

Defining Citation: PMID:1348891, PMID:10408907, PMID:10700188, PMID:11668190, PMID:15126341, PMID:15688027, PMID:20215515, PMID:22460905, PMID:22585861, PMID:25167228, PMID:25485619, PMID:25877200, PMID:26216984, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Name: PaTu 8988t

Synonyms: PA-TU-8988T, PaTu8988t, PaTu8988T, PATU8988T, PaTu 8988 T, PaTu-8988t, PATU-8988T, PATU-T, PA-TU T, 8988T, PaCL4

Cross References: BTO:BTO_0005878, CLO:CLO_0008384, EFO:EFO_0005713, CLDB:cl3862, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:986, BioSample:SAMN03473157, BioSample:SAMN10988386, cancercelllines:CVCL_1847, Cell_Model_Passport:SIDM00453, ChEMBL-Cells:CHEMBL4295420, ChEMBL-Targets:CHEMBL4296488, CLS:305133, Cosmic:873006, Cosmic:948382,

Cosmic:1524020, Cosmic:1995611, Cosmic:2046531, Cosmic:2434111, Cosmic-CLP:1240201, DepMap:ACH-000023, DSMZ:ACC-162, DSMZCellDive:ACC-162, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS158AAA, GDSC:1240201, GEO:GSM206535, GEO:GSM385524, GEO:GSM385535, GEO:GSM816667, GEO:GSM827178, GEO:GSM887504, GEO:GSM888586, GEO:GSM16703371, IGRhCellID:PA-TU-8988T%20GEO, LiGeA:CCLE_005, LINCS_LDP:LCL-1746, PharmacoDB:PATU8988T_1238_2019, PRIDE:PXD030304, Progenetix:CVCL_1847, PubChem_Cell_line:CVCL_1847, Wikidata:Q54938330

ID: CVCL_1847

Record Creation Time: 20220427T221412+0000

Record Last Update: 20250525T112816+0000

Ratings and Alerts

No rating or validation information has been found for PaTu 8988t.

No alerts have been found for PaTu 8988t.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 32 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Wang W, et al. (2024) BUB1 Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Inhibiting Ferroptosis. Cancers, 16(8).

Bhattacharyya S, et al. (2024) Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Nature cancer, 5(2), 283.

Böhme R, et al. (2024) Induction of oxidative- and endoplasmic-reticulum-stress dependent apoptosis in pancreatic cancer cell lines by DDOST knockdown. Scientific reports, 14(1), 20388.

Xiao G, et al. (2024) Citric acid promotes SPARC release in pancreatic cancer cells and inhibits the progression of pancreatic tumors in mice on a high-fat diet. The FEBS journal.

Vogt M, et al. (2024) Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2. Gut, 73(9), 1509.

Sozzi S, et al. (2024) Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis. Journal of experimental & clinical cancer research : CR, 43(1), 265.

Zang L, et al. (2023) Machine learning algorithm integrates bulk and single-cell transcriptome sequencing to reveal immune-related personalized therapy prediction features for pancreatic cancer. Aging, 15(23), 14109.

Dcona MM, et al. (2023) Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer. Cancer research communications, 3(10), 2003.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. Cancer research, 83(9), 1426.

Scharenberg SG, et al. (2023) An SPNS1-dependent lysosomal lipid transport pathway that enables cell survival under choline limitation. Science advances, 9(16), eadf8966.

Bots STF, et al. (2023) Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma. Molecular oncology.

Geismann C, et al. (2023) NF-?B/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Cell death & disease, 14(1), 3.

Abt ER, et al. (2022) Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells. Cell reports, 38(2), 110236.

Lier S, et al. (2022) A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorganic chemistry, 119, 105505.

Santana-Codina N, et al. (2022) NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Cancer discovery, 12(9), 2180.

Zhang W, et al. (2022) A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(23), 5190.

Heid I, et al. (2022) Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Cancer & metabolism, 10(1), 24.

Kim PK, et al. (2021) Hyaluronic acid fuels pancreatic cancer cell growth. eLife, 10.

Krenz B, et al. (2021) MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma. Cancer research, 81(16), 4242.